Glioma
542
127
153
187
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
57 trials with published results (11%)
Research Maturity
187 completed trials (35% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.0%
49 terminated out of 542 trials
79.2%
-7.3% vs benchmark
3%
17 trials in Phase 3/4
30%
57 of 187 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 187 completed trials
Clinical Trials (542)
IL13Rα2 CAR-T for Patients With r/r Glioma
Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients
Language Network Prehab Via fMRI Neurofeedback
Residual IDH1-Mutant Tumor Cell Quantification Study
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
A Phase 1 Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients With Brain Lesions.
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment